FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3193373900> ?p ?o ?g. }

• W3193373900 endingPage "540" @default.
• W3193373900 startingPage "527" @default.
• W3193373900 abstract "Objective To identify predictors of rheumatic immune‐related adverse events (irAEs) following immune checkpoint inhibitor (ICI) treatment for cancer. Methods We performed a case–control study to predict the occurrence of rheumatic irAEs in cancer patients who initiated ICI treatment at Mass General Brigham and the Dana‐Farber Cancer Institute between 2011 and 2020. We screened for the presence of rheumatic irAEs by reviewing the medical records of patients evaluated by rheumatologists or those prescribed nonglucocorticoid immunomodulatory drugs after the time of ICI initiation (baseline). Review of medical records confirmed the presence of rheumatic irAEs and the indications necessitating immunomodulatory drug treatment. Controls were defined as patients who did not experience rheumatic irAEs, did not have preexisting rheumatic disease, did not have a clinical evaluation by a rheumatologist after ICI treatment, did not receive an immunomodulatory drug after ICI, did not receive systemic glucocorticoids after ICI, and survived at least 6 months after the initial ICI treatment. We used logistic regression to estimate the odds ratios (ORs) (with 95% confidence intervals [95% CIs]) for the risk of a rheumatic irAE in the presence of various baseline predictors. Results A total of 8,028 ICI recipients were identified (mean age 65.5 years, 43.1% female, 31.8% with lung cancer). After ICI initiation, 404 patients (5.0%) were evaluated by rheumatologists, and 475 patients (5.9%) received an immunomodulatory drug to treat any irAEs. There were 226 confirmed rheumatic irAE cases (2.8%) and 118 de novo inflammatory arthritis cases (1.5%). Rheumatic diseases (either preexisting rheumatic diseases or rheumatic irAEs) were a common indication for immunomodulatory drug use (27.9%). Baseline predictors of rheumatic irAEs included melanoma (multivariable OR 4.06 [95% CI 2.54–6.51]) and genitourinary (GU) cancer (OR 2.22 [95% CI 1.39–3.54]), both relative to patients with lung cancer; combination ICI treatment (OR 2.35 [95% CI 1.48–3.74]), relative to patients receiving programmed death 1 inhibitor monotherapy; autoimmune disease (OR 2.04 [95% CI 1.45–2.85]) and recent glucocorticoid use (OR 2.13 [95% CI 1.51–2.98]), relative to patients not receiving a glucocorticoid, compared to the 2,312 controls without rheumatic irAEs. Predictors of de novo inflammatory arthritis were similar to those of rheumatic irAEs. Conclusion We identified novel predictors of rheumatic irAE development in cancer patients, including baseline presence of melanoma, baseline presence of GU tract cancer, preexisting autoimmune disease, receiving or having received combination ICI treatment, and receiving or having received glucocorticoids. The proportion of cancer patients experiencing rheumatic irAEs may be even higher than was reported in the present study, since we used stringent criteria to identify cases of rheumatic irAEs. Our findings could be used to identify cancer patients at risk of developing rheumatic irAEs and de novo inflammatory arthritis and may help further elucidate the pathogenesis of rheumatic irAEs in patients with cancer who are receiving ICI treatment." @default.
• W3193373900 created "2021-08-30" @default.
• W3193373900 creator A5003092903 @default.
• W3193373900 creator A5005599468 @default.
• W3193373900 creator A5015009700 @default.
• W3193373900 creator A5018334489 @default.
• W3193373900 creator A5024038808 @default.
• W3193373900 creator A5024906918 @default.
• W3193373900 creator A5029762841 @default.
• W3193373900 creator A5065078602 @default.
• W3193373900 creator A5065331881 @default.
• W3193373900 creator A5067100846 @default.
• W3193373900 creator A5078193406 @default.
• W3193373900 creator A5080783554 @default.
• W3193373900 creator A5081306729 @default.
• W3193373900 creator A5085526843 @default.
• W3193373900 creator A5086249998 @default.
• W3193373900 date "2022-01-25" @default.
• W3193373900 modified "2023-10-16" @default.
• W3193373900 title "Predictors of Rheumatic <scp>Immune‐Related</scp> Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer" @default.
• W3193373900 cites W2061326496 @default.
• W3193373900 cites W2198093519 @default.
• W3193373900 cites W2201214180 @default.
• W3193373900 cites W2441690768 @default.
• W3193373900 cites W2538090159 @default.
• W3193373900 cites W2560367415 @default.
• W3193373900 cites W2562111330 @default.
• W3193373900 cites W2565782504 @default.
• W3193373900 cites W2572174216 @default.
• W3193373900 cites W2600419100 @default.
• W3193373900 cites W2736166064 @default.
• W3193373900 cites W2746214449 @default.
• W3193373900 cites W2747028021 @default.
• W3193373900 cites W2767736444 @default.
• W3193373900 cites W2770072955 @default.
• W3193373900 cites W2779221466 @default.
• W3193373900 cites W2783137027 @default.
• W3193373900 cites W2783621911 @default.
• W3193373900 cites W2786816161 @default.
• W3193373900 cites W2793679501 @default.
• W3193373900 cites W2800772239 @default.
• W3193373900 cites W2805482047 @default.
• W3193373900 cites W2889317689 @default.
• W3193373900 cites W2895392798 @default.
• W3193373900 cites W2896452682 @default.
• W3193373900 cites W2896676995 @default.
• W3193373900 cites W2900174742 @default.
• W3193373900 cites W2943781197 @default.
• W3193373900 cites W2946312326 @default.
• W3193373900 cites W2950056455 @default.
• W3193373900 cites W2966200698 @default.
• W3193373900 cites W2969320113 @default.
• W3193373900 cites W2974173963 @default.
• W3193373900 cites W2977484833 @default.
• W3193373900 cites W2978832429 @default.
• W3193373900 cites W3014279612 @default.
• W3193373900 cites W3018517995 @default.
• W3193373900 cites W3019717295 @default.
• W3193373900 cites W3023745224 @default.
• W3193373900 cites W3034371375 @default.
• W3193373900 cites W3035645886 @default.
• W3193373900 cites W3106838941 @default.
• W3193373900 cites W3107891801 @default.
• W3193373900 cites W3126661349 @default.
• W3193373900 cites W4226322650 @default.
• W3193373900 cites W4288066267 @default.
• W3193373900 doi "https://doi.org/10.1002/art.41949" @default.
• W3193373900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34397169" @default.
• W3193373900 hasPublicationYear "2022" @default.
• W3193373900 type Work @default.
• W3193373900 sameAs 3193373900 @default.
• W3193373900 citedByCount "11" @default.
• W3193373900 countsByYear W31933739002022 @default.
• W3193373900 countsByYear W31933739002023 @default.
• W3193373900 crossrefType "journal-article" @default.
• W3193373900 hasAuthorship W3193373900A5003092903 @default.
• W3193373900 hasAuthorship W3193373900A5005599468 @default.
• W3193373900 hasAuthorship W3193373900A5015009700 @default.
• W3193373900 hasAuthorship W3193373900A5018334489 @default.
• W3193373900 hasAuthorship W3193373900A5024038808 @default.
• W3193373900 hasAuthorship W3193373900A5024906918 @default.
• W3193373900 hasAuthorship W3193373900A5029762841 @default.
• W3193373900 hasAuthorship W3193373900A5065078602 @default.
• W3193373900 hasAuthorship W3193373900A5065331881 @default.
• W3193373900 hasAuthorship W3193373900A5067100846 @default.
• W3193373900 hasAuthorship W3193373900A5078193406 @default.
• W3193373900 hasAuthorship W3193373900A5080783554 @default.
• W3193373900 hasAuthorship W3193373900A5081306729 @default.
• W3193373900 hasAuthorship W3193373900A5085526843 @default.
• W3193373900 hasAuthorship W3193373900A5086249998 @default.
• W3193373900 hasBestOaLocation W31933739002 @default.
• W3193373900 hasConcept C121608353 @default.
• W3193373900 hasConcept C126322002 @default.
• W3193373900 hasConcept C143998085 @default.
• W3193373900 hasConcept C156957248 @default.
• W3193373900 hasConcept C195910791 @default.
• W3193373900 hasConcept C197934379 @default.
• W3193373900 hasConcept C198451711 @default.

• next